KAT5 and breast cancer: Another study showed that low expression of KAT5 led to decreased H3K4 acetylation and knockdown of KAT5 promoted the progression of MDA-MB-231 xenografts, a TNBC model, but not MCF-7 xenografts, an ER-positive breast cancer model [20].